BIOMARIN PHARMACEUTICAL INC APIC, Share-based Payment Arrangement, Increase for Cost Recognition
BIOMARIN PHARMACEUTICAL INC (BMRN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $155.14 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-28.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2019-02-28
- BIOMARIN PHARMACEUTICAL INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2018-12-31 was $39.00M, a 12.48% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2018-09-30 was $38.37M, a 3.00% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2018-06-30 was $40.77M, a 2.54% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2018-03-31 was $37.00M, a 17.37% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2018 was $155.14M, a 6.79% increase from fiscal 2017.
- BIOMARIN PHARMACEUTICAL INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2017 was $145.28M, a 6.31% increase from fiscal 2016.
- BIOMARIN PHARMACEUTICAL INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2016 was $136.66M, a 18.33% increase from fiscal 2015.
- BIOMARIN PHARMACEUTICAL INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2015 was $115.49M, a 30.89% increase from fiscal 2014.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2018-12-31 | $39.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $77.37M derived: sum of 2 quarters · filed 2019-02-28 | $118.14M derived: sum of 3 quarters · filed 2019-02-28 | $155.14M 10-K · filed 2019-02-28 |
| 2018-09-30 | $38.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-26 | $79.14M derived: sum of 2 quarters · filed 2018-10-26 | $116.14M 10-Q · filed 2018-10-26 | $150.81M derived: sum of 4 quarters · filed 2019-02-28 |
| 2018-06-30 | $40.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $77.77M 10-Q · filed 2018-08-03 | $112.44M derived: sum of 3 quarters · filed 2019-02-28 | $149.69M derived: sum of 4 quarters · filed 2019-02-28 |
| 2018-03-31 | $37.00M 10-Q · filed 2018-04-27 | $71.67M derived: sum of 2 quarters · filed 2019-02-28 | $108.92M derived: sum of 3 quarters · filed 2019-02-28 | $150.75M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-12-31 | $34.67M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $71.92M derived: sum of 2 quarters · filed 2019-02-28 | $113.76M derived: sum of 3 quarters · filed 2019-02-28 | $145.28M 10-K · filed 2019-02-28 |
| 2017-09-30 | $37.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $79.08M derived: sum of 2 quarters · filed 2017-10-31 | $110.61M 10-Q · filed 2017-10-31 | $147.26M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $41.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $73.36M 10-Q · filed 2017-08-02 | $110.01M derived: sum of 3 quarters · filed 2019-02-28 | $144.18M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $31.52M 10-Q · filed 2017-05-04 | $68.18M derived: sum of 2 quarters · filed 2019-02-28 | $102.34M derived: sum of 3 quarters · filed 2019-02-28 | $137.17M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $36.66M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $70.82M derived: sum of 2 quarters · filed 2019-02-28 | $105.65M derived: sum of 3 quarters · filed 2019-02-28 | $136.66M 10-K · filed 2019-02-28 |
| 2016-09-30 | $34.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $68.99M derived: sum of 2 quarters · filed 2016-11-03 | $100.01M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $34.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $65.84M 10-Q · filed 2016-08-08 | ||
| 2016-03-31 | $31.02M 10-Q · filed 2016-05-02 | |||
| 2015-12-31 | $115.49M 10-K · filed 2018-02-26 | |||
| 2014-12-31 | $88.23M 10-K · filed 2017-02-27 | |||
| 2013-12-31 | $66.18M 10-K · filed 2016-02-29 | |||
| 2012-12-31 | $47.34M 10-K · filed 2015-03-02 | |||
| 2011-12-31 | $43.91M 10-K · filed 2014-02-26 | |||
| 2010-12-31 | $38.36M 10-K · filed 2013-02-26 | |||
| 2009-12-31 | $36.01M 10-K · filed 2012-02-22 | |||
| 2008-12-31 | $28.34M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |